ID   GWL_HUMAN               Reviewed;         879 AA.
AC   Q96GX5; Q5T8D5; Q5T8D7; Q8NCD6; Q96SJ5;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   12-OCT-2022, entry version 183.
DE   RecName: Full=Serine/threonine-protein kinase greatwall;
DE            Short=GW;
DE            Short=GWL;
DE            Short=hGWL;
DE            EC=2.7.11.1;
DE   AltName: Full=Microtubule-associated serine/threonine-protein kinase-like;
DE            Short=MAST-L;
GN   Name=MASTL; Synonyms=GW, GWL, THC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370; SER-657 AND SER-878, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-293; SER-370; SER-552;
RP   SER-556; THR-722; SER-725; THR-741; SER-875 AND SER-878, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   FUNCTION.
RX   PubMed=19680222; DOI=10.1038/emboj.2009.228;
RA   Vigneron S., Brioudes E., Burgess A., Labbe J.C., Lorca T., Castro A.;
RT   "Greatwall maintains mitosis through regulation of PP2A.";
RL   EMBO J. 28:2786-2793(2009).
RN   [9]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANT ASP-167.
RX   PubMed=19460416; DOI=10.1016/j.exphem.2009.05.005;
RA   Johnson H.J., Gandhi M.J., Shafizadeh E., Langer N.B., Pierce E.L.,
RA   Paw B.H., Gilligan D.M., Drachman J.G.;
RT   "In vivo inactivation of MASTL kinase results in thrombocytopenia.";
RL   Exp. Hematol. 37:901-908(2009).
RN   [10]
RP   FUNCTION.
RX   PubMed=19793917; DOI=10.1091/mbc.e09-07-0643;
RA   Castilho P.V., Williams B.C., Mochida S., Zhao Y., Goldberg M.L.;
RT   "The M phase kinase Greatwall (Gwl) promotes inactivation of PP2A/B55delta,
RT   a phosphatase directed against CDK phosphosites.";
RL   Mol. Biol. Cell 20:4777-4789(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=20818157; DOI=10.4161/cc.9.17.12832;
RA   Voets E., Wolthuis R.M.F.;
RT   "MASTL is the human orthologue of Greatwall kinase that facilitates mitotic
RT   entry, anaphase and cytokinesis.";
RL   Cell Cycle 9:3591-3601(2010).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=20538976; DOI=10.1073/pnas.0914191107;
RA   Burgess A., Vigneron S., Brioudes E., Labbe J.-C., Lorca T., Castro A.;
RT   "Loss of human Greatwall results in G2 arrest and multiple mitotic defects
RT   due to deregulation of the cyclin B-Cdc2/PP2A balance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:12564-12569(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-207; THR-222; SER-370;
RP   SER-631; SER-668; SER-875 AND SER-878, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-72.
RX   PubMed=21164014; DOI=10.1126/science.1197048;
RA   Gharbi-Ayachi A., Labbe J.C., Burgess A., Vigneron S., Strub J.M.,
RA   Brioudes E., Van-Dorsselaer A., Castro A., Lorca T.;
RT   "The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting
RT   protein phosphatase 2A.";
RL   Science 330:1673-1677(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370; SER-453; THR-519;
RP   SER-657 AND SER-878, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   VARIANT ASP-167, FUNCTION, AND POSSIBLE INVOLVEMENT IN THROMBOCYTOPENIA.
RX   PubMed=12890928; DOI=10.1159/000071812;
RA   Gandhi M.J., Cummings C.L., Drachman J.G.;
RT   "FLJ14813 missense mutation: a candidate for autosomal dominant
RT   thrombocytopenia on human chromosome 10.";
RL   Hum. Hered. 55:66-70(2003).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-337; ILE-610 AND ALA-620.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase that plays a key role in M phase by
CC       acting as a regulator of mitosis entry and maintenance. Acts by
CC       promoting the inactivation of protein phosphatase 2A (PP2A) during M
CC       phase: does not directly inhibit PP2A but acts by mediating
CC       phosphorylation and subsequent activation of ARPP19 and ENSA at 'Ser-
CC       62' and 'Ser-67', respectively. ARPP19 and ENSA are phosphatase
CC       inhibitors that specifically inhibit the PPP2R2D (PR55-delta) subunit
CC       of PP2A. Inactivation of PP2A during M phase is essential to keep
CC       cyclin-B1-CDK1 activity high. Following DNA damage, it is also involved
CC       in checkpoint recovery by being inhibited. Phosphorylates histone
CC       protein in vitro; however such activity is unsure in vivo. May be
CC       involved in megakaryocyte differentiation.
CC       {ECO:0000269|PubMed:12890928, ECO:0000269|PubMed:19680222,
CC       ECO:0000269|PubMed:19793917, ECO:0000269|PubMed:20538976,
CC       ECO:0000269|PubMed:20818157}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:21164014};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:21164014};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:20818157}. Nucleus
CC       {ECO:0000269|PubMed:19460416, ECO:0000269|PubMed:20818157}. Cleavage
CC       furrow {ECO:0000269|PubMed:20818157}. Note=During interphase is mainly
CC       nuclear, upon nuclear envelope breakdown localizes at the cytoplasm and
CC       during mitosis at the centrosomes. Upon mitotic exit moves to the
CC       cleavage furrow. {ECO:0000269|PubMed:20818157}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96GX5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96GX5-2; Sequence=VSP_014574, VSP_014575;
CC       Name=3;
CC         IsoId=Q96GX5-3; Sequence=VSP_014574;
CC   -!- PTM: Phosphorylation at Thr-741 by CDK1 during M phase activates its
CC       kinase activity (By similarity). Maximum phosphorylation occurs in
CC       prometaphase. {ECO:0000250, ECO:0000269|PubMed:20538976,
CC       ECO:0000269|PubMed:20818157}.
CC   -!- DISEASE: Note=Defects in MASTL may play a role in the pathogenesis of
CC       thrombocytopenia, a disorder defined by reduced number of platelets in
CC       circulating blood, resulting in the potential for increased bleeding
CC       and decreased ability for clotting. {ECO:0000269|PubMed:12890928}.
CC   -!- MISCELLANEOUS: Reduced levels of MASTL by RNAi causes mitotic
CC       abnormalities that consist of delay in G(2) phase and slow chromosome
CC       condensation. Cells that enter and progress through mitosis often fail
CC       to completely separate their sister chromatids in anaphase leading to
CC       the formation of 4N G(1) cells subsequent to failure of cytokinesis
CC       (PubMed:20818157 and PubMed:20538976).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK027719; BAB55321.1; -; mRNA.
DR   EMBL; AK074804; BAC11218.1; -; mRNA.
DR   EMBL; AL160291; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009107; AAH09107.1; -; mRNA.
DR   CCDS; CCDS53502.1; -. [Q96GX5-1]
DR   CCDS; CCDS53503.1; -. [Q96GX5-2]
DR   CCDS; CCDS7153.1; -. [Q96GX5-3]
DR   RefSeq; NP_001165774.1; NM_001172303.2. [Q96GX5-1]
DR   RefSeq; NP_001165775.1; NM_001172304.2. [Q96GX5-2]
DR   RefSeq; NP_116233.2; NM_032844.4. [Q96GX5-3]
DR   PDB; 5LOH; X-ray; 3.10 A; A/B=1-194, A/B=740-879.
DR   PDBsum; 5LOH; -.
DR   AlphaFoldDB; Q96GX5; -.
DR   SMR; Q96GX5; -.
DR   BioGRID; 124364; 51.
DR   IntAct; Q96GX5; 25.
DR   MINT; Q96GX5; -.
DR   STRING; 9606.ENSP00000365107; -.
DR   ChEMBL; CHEMBL4105826; -.
DR   GlyGen; Q96GX5; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96GX5; -.
DR   PhosphoSitePlus; Q96GX5; -.
DR   BioMuta; MASTL; -.
DR   DMDM; 68565604; -.
DR   EPD; Q96GX5; -.
DR   jPOST; Q96GX5; -.
DR   MassIVE; Q96GX5; -.
DR   MaxQB; Q96GX5; -.
DR   PaxDb; Q96GX5; -.
DR   PeptideAtlas; Q96GX5; -.
DR   PRIDE; Q96GX5; -.
DR   ProteomicsDB; 76677; -. [Q96GX5-1]
DR   ProteomicsDB; 76678; -. [Q96GX5-2]
DR   ProteomicsDB; 76679; -. [Q96GX5-3]
DR   Antibodypedia; 12704; 357 antibodies from 31 providers.
DR   DNASU; 84930; -.
DR   Ensembl; ENST00000342386.10; ENSP00000343446.5; ENSG00000120539.15. [Q96GX5-2]
DR   Ensembl; ENST00000375940.9; ENSP00000365107.5; ENSG00000120539.15. [Q96GX5-1]
DR   Ensembl; ENST00000375946.8; ENSP00000365113.4; ENSG00000120539.15. [Q96GX5-3]
DR   GeneID; 84930; -.
DR   KEGG; hsa:84930; -.
DR   MANE-Select; ENST00000375940.9; ENSP00000365107.5; NM_001172303.3; NP_001165774.1.
DR   UCSC; uc001itl.3; human. [Q96GX5-1]
DR   CTD; 84930; -.
DR   DisGeNET; 84930; -.
DR   GeneCards; MASTL; -.
DR   HGNC; HGNC:19042; MASTL.
DR   HPA; ENSG00000120539; Low tissue specificity.
DR   MalaCards; MASTL; -.
DR   MIM; 608221; gene.
DR   neXtProt; NX_Q96GX5; -.
DR   OpenTargets; ENSG00000120539; -.
DR   Orphanet; 168629; Autosomal thrombocytopenia with normal platelets.
DR   PharmGKB; PA134943781; -.
DR   VEuPathDB; HostDB:ENSG00000120539; -.
DR   eggNOG; KOG0606; Eukaryota.
DR   GeneTree; ENSGT00940000157002; -.
DR   HOGENOM; CLU_016048_0_0_1; -.
DR   InParanoid; Q96GX5; -.
DR   OMA; STSHTPY; -.
DR   OrthoDB; 878671at2759; -.
DR   PhylomeDB; Q96GX5; -.
DR   TreeFam; TF313149; -.
DR   PathwayCommons; Q96GX5; -.
DR   Reactome; R-HSA-2465910; MASTL Facilitates Mitotic Progression.
DR   SignaLink; Q96GX5; -.
DR   SIGNOR; Q96GX5; -.
DR   BioGRID-ORCS; 84930; 739 hits in 1063 CRISPR screens.
DR   ChiTaRS; MASTL; human.
DR   GeneWiki; MASTL; -.
DR   GenomeRNAi; 84930; -.
DR   Pharos; Q96GX5; Tbio.
DR   PRO; PR:Q96GX5; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q96GX5; protein.
DR   Bgee; ENSG00000120539; Expressed in secondary oocyte and 151 other tissues.
DR   ExpressionAtlas; Q96GX5; baseline and differential.
DR   Genevisible; Q96GX5; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; ISS:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; ISS:UniProtKB.
DR   GO; GO:0007147; P:female meiosis II; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0000278; P:mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0032515; P:negative regulation of phosphoprotein phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:1904668; P:positive regulation of ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   CDD; cd05610; STKc_MASTL; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR037638; MASTL_STKc.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle;
KW   Cell division; Cytoplasm; Cytoskeleton; Disease variant; Kinase; Mitosis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..879
FT                   /note="Serine/threonine-protein kinase greatwall"
FT                   /id="PRO_0000086315"
FT   DOMAIN          35..835
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          836..879
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          566..632
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          700..728
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        566..588
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        700..720
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        156
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         41..49
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         62
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         207
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         222
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         293
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         370
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         453
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         519
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         552
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         556
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         631
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         657
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         668
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         722
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         725
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         741
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         875
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         878
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         708
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_014574"
FT   VAR_SEQ         756..793
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_014575"
FT   VARIANT         167
FT                   /note="E -> D (found in a large family with autosomal
FT                   dominant thrombocytopenia; unknown pathological
FT                   significance; no effect on nuclear localization;
FT                   dbSNP:rs28941470)"
FT                   /evidence="ECO:0000269|PubMed:12890928,
FT                   ECO:0000269|PubMed:19460416"
FT                   /id="VAR_022838"
FT   VARIANT         337
FT                   /note="T -> K (in dbSNP:rs36121140)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040792"
FT   VARIANT         606
FT                   /note="D -> Y (in dbSNP:rs35413630)"
FT                   /id="VAR_057103"
FT   VARIANT         610
FT                   /note="V -> I (in dbSNP:rs35571315)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040793"
FT   VARIANT         620
FT                   /note="P -> A (in dbSNP:rs3802526)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_022839"
FT   MUTAGEN         72
FT                   /note="K->M: Hyperactive form."
FT                   /evidence="ECO:0000269|PubMed:21164014"
FT   CONFLICT        634
FT                   /note="K -> E (in Ref. 1; BAC11218)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        685
FT                   /note="C -> R (in Ref. 1; BAB55321)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        731
FT                   /note="A -> P (in Ref. 1; BAC11218)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        865
FT                   /note="A -> T (in Ref. 1; BAB55321)"
FT                   /evidence="ECO:0000305"
FT   HELIX           32..34
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          35..40
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          48..56
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          58..65
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   TURN            66..68
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          96..98
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          103..111
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   HELIX           118..125
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   HELIX           130..149
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   TURN            159..161
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          162..164
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          170..172
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   STRAND          174..177
FT                   /evidence="ECO:0007829|PDB:5LOH"
FT   HELIX           200..203
FT                   /evidence="ECO:0007829|PDB:5LOH"
SQ   SEQUENCE   879 AA;  97319 MW;  E6533029D1CE58B4 CRC64;
     MDPTAGSKKE PGGGAATEEG VNRIAVPKPP SIEEFSIVKP ISRGAFGKVY LGQKGGKLYA
     VKVVKKADMI NKNMTHQVQA ERDALALSKS PFIVHLYYSL QSANNVYLVM EYLIGGDVKS
     LLHIYGYFDE EMAVKYISEV ALALDYLHRH GIIHRDLKPD NMLISNEGHI KLTDFGLSKV
     TLNRDINMMD ILTTPSMAKP RQDYSRTPGQ VLSLISSLGF NTPIAEKNQD PANILSACLS
     ETSQLSQGLV CPMSVDQKDT TPYSSKLLKS CLETVASNPG MPVKCLTSNL LQSRKRLATS
     SASSQSHTFI SSVESECHSS PKWEKDCQES DEALGPTMMS WNAVEKLCAK SANAIETKGF
     NKKDLELALS PIHNSSALPT TGRSCVNLAK KCFSGEVSWE AVELDVNNIN MDTDTSQLGF
     HQSNQWAVDS GGISEEHLGK RSLKRNFELV DSSPCKKIIQ NKKTCVEYKH NEMTNCYTNQ
     NTGLTVEVQD LKLSVHKSQQ NDCANKENIV NSFTDKQQTP EKLPIPMIAK NLMCELDEDC
     EKNSKRDYLS SSFLCSDDDR ASKNISMNSD SSFPGISIME SPLESQPLDS DRSIKESSFE
     ESNIEDPLIV TPDCQEKTSP KGVENPAVQE SNQKMLGPPL EVLKTLASKR NAVAFRSFNS
     HINASNNSEP SRMNMTSLDA MDISCAYSGS YPMAITPTQK RRSCMPHQQT PNQIKSGTPY
     RTPKSVRRGV APVDDGRILG TPDYLAPELL LGRAHGPAVD WWALGVCLFE FLTGIPPFND
     ETPQQVFQNI LKRDIPWPEG EEKLSDNAQS AVEILLTIDD TKRAGMKELK RHPLFSDVDW
     ENLQHQTMPF IPQPDDETDT SYFEARNTAQ HLTVSGFSL
//
